CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating webbased and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

a) a guide for reporting for authors of RCTs,

b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *. In the textboxes, either copy & paste the relevant sections from your manuscript into this form please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption): Eysenbach G, CONSORT-EHEALTH Group CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions J Med Internet Res 2011;13(4):e126 URL: <u>http://www.jmir.org/2011/4/e126/</u> doi: 10.2196/jmir.1923 PMID: 22209829

* Erforderlich

Your name * First Last

Lena Jelinek

Primary Affiliation (short), City, Country *

University of Toronto, Toronto, Canada

University Medical Center Hamburg-Epp

Your e-mail address * abc@gmail.com

ljelinek@uke.de

Title of your manuscript *

Provide the (draft) title of your manuscript.

Brief Web-based Intervention for Depression: A Randomized Controlled Trial on BehavionActivation (STRONG-study)

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

iBA (internet-based behavioral activatior

Evaluated Version (if any)


e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Meine Antwort

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

German



Unipolar Depression

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

PHQ-9

Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

Behavioral Activation for Depression Scale (BADS), Kentucky Inventory of Mindfulness Skills (KIMS-D), Dysfunctional Attitude Scale (DAS), The World Health Organization Quality of Life (WHOQOL)

Recommended "Dose" *

What do the instructions for users say on how often the app should be used?

- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- 🔵 "as needed"
- Sonstiges:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months *	
Inknown / not evaluated	
0-10%	
0 11-20%	
0 21-30%	
0 31-40%	
O 41-50%	
51-60%	
0 61-70%	
0 71%-80%	
0 81-90%	
91-100%	
O Sonstiges:	

Overall, was the app/intervention effective? *
O yes: all primary outcomes were significantly better in intervention group vs control
O partly: SOME primary outcomes were significantly better in intervention group vs control
O no statistically significant difference between control and intervention
O potentially harmful: control was significantly better than intervention in one or more outcomes
O inconclusive: more research is needed
Sonstiges: statistically significant differences in secondary outcomes
Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
O not submitted yet - in early draft status
ont submitted yet - in late draft status, just before submission
Submitted to a journal but not reviewed yet
O submitted to a journal and after receiving initial reviewer comments
Submitted to a journal and accepted, but not published yet
O published
O Sonstiges:

Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Sonstiges:

Is this a full powered effectiveness trial or a pilot/feasibility trial?




Fully powered

Manuscript tracking number *

TITLE AND ABSTRACT

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the fourdigit number at the end of the DOI, to be found at the bottom of each published article in JMIR)



1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *


I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")



Sonstiges:

1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.




Does your paper address subitem 1a-i?*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"BriefeWeb+based Intervention for Depression"

1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").



Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

	1	2	3	4	5	
subitem not at all important	\bigcirc	0	\bigcirc	۲	0	essential

Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Vor Depression"

1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential

Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"a single-module, fully automated, distinct intervention for depression (internetbased behavioral activation, iBA)"

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	\bigcirc	\bigcirc	\bigcirc	\bigcirc	۲	essential

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The aim of the present pilot study was to shed light on mechanisms in the online treatment of depression by comparing a single-module, fully automated, distinct intervention for depression (internet-based behavioral activation, iBA) to a non-overlapping active, fully automated control intervention and a non-active control group."

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-toface assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)




Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"We assessed 104 people with at least mild depressive symptoms (PHQ-9 > 4) via the internet."

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"1) iBA (n = 37), 2) brief internet-based mindfulness (iM, active control, n = 32), or 3) care as usual (CAU, n = 35)"

"22 % participants in the iBA group (n=6) and 12 % participants in the iM group (n=3) indicated that they did not use the intervention."

"While groups neither differ regarding change in depression from t0 to t1 (η p2 =.007, P=.746,) nor from t0 to t2 (η p2 = .008, P=.735), iBA was associated with a larger decrease in dysfunctional attitudes (DAS) from t0 to t2 (η p2 = .053, P = .04) and a larger increase in activity (BADS) from t0 to t1(η p2 = .060, P = .02) in comparison to the pooled control groups."

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	\bigcirc	0	\bigcirc	\bigcirc	۲	essential

Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"While we did not find support for the short-term efficacy of one-module iBA regarding depression, long-term effects are still conceivable (potentially initiated by change in secondary outcomes). Future studies should use a longer intervention and follow-up interval. "

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as standalone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)



Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Generally research on mechanisms of changes is challenging, due to methodological characteristics involved in the design of psychotherapeutic trials that often complicate analyses [20,i.e. focus on overall effect, see 21] as well as the complexity of most psychological treatments"; "The aim of the present study was to use a maximum focused approach in assessing short-term effects of brief web-based interventions and potential mechanisms of change." Meine Antwort

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.



E

Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Generally research on mechanisms of changes is challenging (for problems in dismanteling and component studies in depression see [20])". "The complexity of POIs, where different interventions are typically spread across several modules, is further exacerbated by rather low adherence rates (only 80 % of the offered modules being completed by participants) and high drop-out rates of 37 % [5]. Furthermore, in some POIs modules are self-selected and participants can choose which modules they want to complete, or modules are presented stepwise. Thus, in POIs it may be particularly difficult to capture the (interacting) effect of different interventions as not all participants receive the same components of a therapy."

"As a stand-alone intervention for depression, BA has been found similar effective as CBT in face-to-face treatment."

"Still, as for other interventions, mechanims of actions are unclear for BA [31]. Regarding internet delivered BA (iBA), a recent meta-analysis by Huguet et al. [32] supports its effectiveness, although conclusions were compromised by the low quality of studies. In this meta-analysis, iBA interventions lasted between 6 to 17 weeks. One of the studies [33] included in this meta-analysis compared BA to physical activity and a waitlist control. In this study, the authors showed that depression decreased more in the treatment groups compared to the waitlist control group. There was no relation between the number of used modules and decrease of symptoms. Thus, it remains unclear how many modules/sessions of iBA are needed to achieve a response. Another intervention that is often used in combination with CBT in depression is mindfulness (i.e., mindfulness-based cognitive therapy, MBCT). In face-to-face treatment, some evidence suggests the effectiveness of MBCT on depression [34]. When mindfulness-based interventions (not limited to MBCT) were administered online, metaanalyses have shown small to large effects with a Hedges' g between g = 0.29 [35] and g = -0.61 [36] for the general decrease of depressive symptoms. However, effects were non-significant in the meta-analysis by Sevilla-Llewellyn-Jones et al. [36] when participants with depression were considered only (g=-0.690, 95% CI -1.694 to -0.313, P = .19). " "With regard to overlap in contents (psychoeducation) and specific

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dG... 14/50

Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"As Ly et al. [38], we expect a reduction in both primary and secondary outcomes in favor of the experimental intervention (iBA) in comparison to the active (iM) and non-active (CAU) control group. Moreover, we planned mediation analyses to investigate mechanism of change. We expected that an improvement in depressive symptoms at t2 would be mediated by change in activation (BADS) between t0 and t1."

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Group allocation (randomization to one of the three groups with an allocation ratio of 1:1:1) was performed according to the point in time when the baseline survey was completed by a person who did not possess any other information on the respective participant. The procedure has been referred to as centralized assignment [39]."

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Some changes were made after the trial had been registered: An additional aim of the original study was to recruit treatment seeking outpatients through medical staff at the hospital. As this let to very low participation, we decided to recruit through online advertisements instead. Therefore, depressive symptoms according the PHQ-9 instead of depressive disorder as diagnosed by a therapist/practitioner was used as

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].



Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Inclusion criteria were depressive symptoms according to self-report (PHQ total score > 4 indicating mild depression, age between 18 and 65 years, internet access, sufficient language skills (German), informed consent (including the willingness to participate in three online assessments and in a two-week intervention). Exclusion criteria were lifetime psychotic or manic symptoms and suicidality (as indicated by a score > 2 on the BDI-2 suicide item). "

Meine Antwort

4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

	1	2	3	4	5	
subitem not at all important	\bigcirc	0	۲	\bigcirc	0	essential

Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in guotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Inclusion criteria were depressive symptoms according to self-report (PHQ total score > 4 indicating mild depression, age between 18 and 65 years, internet access as well as internet literacy, sufficient language skills (German), informed consent (including the willingness to participate in three online assessments and in a two-week intervention)."

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	0	0	۲	0	0	essential

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Recruitment took place between April 18,2018 and May 27,2018 via a Google AdWords campaign. Moreover, the link of the study was sendsent to participants of previous studies who had provided written consent to be contacted again via email."

"After randomization, participants of the iBA and iM group received a link, code and password to access the respective online treatment. They could use the treatment according to their needs regarding time, pace, and frequency. Two weeks and four weeks later, all participants of the intention-to-treat sample were sent a link for re-assessment. To increase the retention rate, participants were reminded every two days to fill in the survey (up to three times in total). After completion of 4-weeks assessment, all participants received the links, codes and passwords to access both treatments.

In total 1,156 people accessed the survey (see Figure 1). The majority did not finish the baseline survey (n = 1,050) and assessment was automatically terminated in two participants due to exclusion criteria (n = 2/suicidality, see inclusion criteria) leaving 104 participants for the

4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.



Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Recruitment took place between April 18,2018 and May 27,2018 via a Google AdWords campaign. Moreover, the link of the study was sendsent to participants of previous studies who had provided written consent to be contacted again via emails"Antwort

4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in webbased trials) or otherwise.

	1	2	3	4	5	
subitem not at all important	\bigcirc	0	۲	\bigcirc	0	essential

Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants were assessed online using the online survey program "EFS survey" developed/by/Questback®. "

4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)



Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see authors

5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.



Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).



Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable

5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.



Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see Appendix A for screenshot

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	\bigcirc	0	0	\bigcirc	0	essential


Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).



Does your paper address subitem 5-vii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"After randomization, participants of the iBA and iM group received a link, code and password to access the respective online treatment. They could use the treatment according to their needs regarding time, pace, and frequency. Two weeks and four weeks later, all participants of the intention-to-treat sample were sent a link for re-assessment. To increase the retention rate, participants were reminded every two days to fill in the survey (up to three times in total). After completion of 4-weeks assessment, all participants received the links, codes and passwords to

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].



Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The iBA is a web-based intervention focusing on the development of behavioral activities. It is based on the German version of the manual by Martell et al. [40]. The intervention starts with psychoeducation on the interplay between mood and behavior in depression. Then, patients learn to assess their mood and daily activities, which types of activities and rewards there are, how to sensibly plan activities in their daily schedule as well as anticipating problems that may come up when trying to perform the planned activities. Most of the information is accompanied by worksheets. Depending on the reading rate and personal processing time, it takes about 60 minutes to complete the module, however patients are advised to take their time and use the program on a daily level. For a web browser screenshot of the intervention please see Appendix A.

Internet-Based Mindfulness (iM, active control group)

The iM is a web-based intervention introducing and teaching mindfulness practice. It is based on the German version of the mindfulness manual by Segal Teasdale, and Williams [41]. It starts with an introduction into the concept of mindfulness and an explanation how mindfulness could help depressed persons. In the following sections patients independently carry out mindfulness exercises using audio files (breathing exercise, body scan, inner smile). Furthermore, they can use worksheets to detect situations, in which they are not mindful (automatic pilot), how to mindfully deal with disturbing thoughts and feelings ("thoughts are not facts"), how to enhance self-care through mindfulness. Depending on the reading rate and personal processing time, it takes about 60 minutes to complete the worksheets. Similar to the BA intervention, patients are advised to use the exercises in their daily life and to use the program repeatedly. "

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.



Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The iBA is a web-based intervention focusing on the development of behavioral activities. It is based on the German version of the manual by Martell et al. [40]. The intervention starts with psychoeducation on the interplay between mood and behavior in depression. Then, patients learn to assess their mood and daily activities, which types of activities and rewards there are, how to sensibly plan activities in their daily schedule as well as anticipating problems that may come up when trying to perform the planned activities. Most of the information is accompanied by worksheets. Depending on the reading rate and personal processing time, it takes about 60 minutes to complete the module, however patients are advised to take their time and use the program on a daily level. For a web browser screenshot of the intervention please see Appendix A."

"The iM is a web-based intervention introducing and teaching mindfulness practice. It is based on the German version of the mindfulness manual by Segal Teasdale, and Williams [41]. It starts with an introduction into the concept of mindfulness and an explanation how mindfulness could help depressed persons. In the following sections patients independently carry out mindfulness exercises using audio files (breathing exercise, body scan, inner smile). Furthermore, they can use worksheets to detect situations, in which they are not mindful (automatic pilot), how to mindfully deal with disturbing thoughts and feelings ("thoughts are not facts"), how to enhance self-care through mindfulness. Depending on the reading rate and personal processing time, it takes about 60 minutes to complete the worksheets. Similar to the BA intervention, patients are advised to use the exercises in their daily life and to use the program repeatedly. "

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	\bigcirc	0	0	0	\bigcirc	essential

Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"fully automated"

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



Does your paper address subitem 5-xi? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Both online interventions were unguided. All information on how to use the interventions was given in each of the programs; we did not provide any additional information. The interventions consisted of **psychoeducational** information as well as worksheets. For iM that also

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"CAblincluded full access to treatment as usual. "

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

Does your paper address CONSORT subitem 6a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Primary Outcome

Patient Health Questionnaire (PHQ-9)

Severity of depression was measured by the German Version of the PHQ-9 [43]. The PHQ-9 represents the depression module of the PHQ-D using 9 items rated on a 4-point Likert-scale. Good validity and reliability has been reported [43,44].

Secondary Outcomes

Behavioral Activation for Depression Scale (BADS) The German version of the BADS [45] was used to assess levels of behavioral activation. It includes 25 items summarized in a total score. Internal consistency and test-retest reliability are considered acceptable [46].

Kentucky Inventory of Mindfulness Skills (KIMS-D) Dispositional mindfulness was assessed with the German version of the

20-item-version of the KIMS [47]. Psychometric properties of the KIMS, including sensitivity of change are considered good [48].

Dysfunctional Attitude Scale (DAS-18B)

The German 18-item version of the DAS (form B) was used to assess dysfunctional beliefs (Rojas, Geissner, & Hautzinger, 2015). Items are rated on a 7-point Likert scale. Reliability and validity of the scale is good [49].

The World Health Organization Quality of Life (WHOQOL) Quality of life was assessed with the global item of the German version of the WHOQOL-BREF [50]. "

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

Meine Antwort

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential


Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

"At the 2-weeks assessment, 6 participants in the iBA group (22 %) and 3 participants in the iM group (12 %) indicated that they did not use the respective online module at all. "

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).



Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

hoechanges ort

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.

	1	2	3	4	5	
subitem not at all important	\bigcirc	0	0	0	0	essential

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

hoeinterim analyses

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"GGroup allocation (randomization to one of the three groups with an allocation ratio of 1:1:1) was performed according to the point in time when the baseline survey was completed by a person who did not possess any other information on the respective participant. The procedure has been referred to as centralized assignment [39]. "

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

hoerestrictionrt

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Group allocation (randomization to one of the three groups with an allocation ratio of 1:1:1) was performed according to the point in time when the baseline survey was completed by a person who did not possess any other information on the respective participant. The procedure has been referred to as centralized assignment [39]."

10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Group allocation (randomization to one of the three groups with an allocation ratio of 1:1:1) was performed according to the point in time when the baseline survey was completed by a person who did not possess any other information on the respective participant. The procedure has been referred to as centralized assignment [39]."

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).



Does your paper address subitem 11a-i?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".



Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Experimental and active control intervention (iBA and iM) were presented as techniques to target depressive symptoms.

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"With regard to overlap in contents (psychoeducation) and specific interventions (techniques and skills given to patients), we regarded the overlap between BA and mindfulness as minimal. "

12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Strategy of Data Analysis

IBM SPSS 25.0 software was used for all analyses [49]. We conducted complete-cases (CC) as well as intention-to-treat (ITT) analyses. CC analyses was based on data from participants that had been assessed at all three assessment points. For ITT analyses, which included all randomized patients, missing data was imputed by multiple imputations based on the assumption that data were missing at random conditional on information on treatment, sex, age, and all relevant outcomes across the three time points of assessment. We created 100 imputed datasets. To investigate efficacy, we conducted analyses of covariance (ANCOVA) with treatment (iBA, iM, CAU) as the independent factor, baseline level of the respective outcome as the covariate, and the level of the outcome at 2weeks and 4-weeks assessment, respectively, as the dependent variable. To follow up group differences, control groups were pooled contrasting the experimental group (iBA) with the control groups (iM and CAU). For posthoc tests on an individual group level, we used uncorrected t-tests. Effect sizes for ANCOVAs are reported according to Kinnear and Gray [50] with $\eta p2 \approx .01$, $\eta p2 \approx .06$, and $\eta p2 \approx .14$, corresponding to small, medium, and large effects, respectively."

Meine Antwort

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

	1	2	3	4	5	
subitem not at all important	0	0	\bigcirc	\bigcirc	\bigcirc	essential

Does your paper address subitem 12a-i?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"For ITT analyses, which included all randomized patients, missing data was imputed by multiple imputations based on the assumption that data were missing at random conditional on information on treatment, sex, age, and all relevant outcomes across the three time points of assessment. We created 100 imputed datasets. "

"For mediation analyses, we performed a secondary analysis to impute missing data, that is, expectation-maximization (EM) algorithm. This was necessary because multiple imputation data sets cannot be used in PROCESS."

Meine Antwort

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"To investigate involved mechanisms of change, we conducted mediation analyses [15]. We coded BA as 1 and pooled the control groups (iM and CAU) and coded them as 0, with thus treatment effect referring to effects of iBA above and beyond the pooled control groups. We computed standardized residualized change scores for change in depression from baseline to 4-weeks assessment (PHQ-9) and for change in mediators (BADS, KIMS, DAS) from baseline to 2-weeks assessment (see figure 2 for an overview). The mediation analyses performed using the SPSS macro PROCESS developed by Hayes (version v3.1) [53] met all of the criteria defined by Kraemer and colleagues [54] for the use of mediators within an RCT. We bootstrapped the results 5,000 times to correct for potential biases of non-normality in the sample. For mediation analyses, we performed a secondary analysis to impute missing data, that is, expectation-maximization (EM) algorithm. This was necessary because multiple imputation data sets cannot be used in PROCESS. The mediation hypothesis is confirmed, when the effect range (LL = lower limit to UL =

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)									
X26-i) Comment on et	hics co	ommit	tee ap	proval					
	1	2	3	4	5				
subitem not at all important	0	0	0	0	٢	essential			
Copy and paste relevant sections f to indicate direct quotes from your information not in the ms, or briefly	Does your paper address subitem X26-i? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study								
"The trial was approved by t Association (比J032018_am			nillee o	i the Ge		sychological			
Outline informed consent procedu Checkbox, etc.?), and what informa	x26-ii) Outline informed consent procedures Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents. 1 2 3 4 5								
subitem not at all important	0	0	0	0	۲	essential			
Does your paper address subitem X26-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "All participants provided electronic informed consent"									
X26-iii) Safety and sec Safety and security procedures, ind likelihood or detection of harm (e.g	cl. privacy	, consider	ations, ar	-					
	1	2	3	4	5				
subitem not at all important	0	0	0	0	0	essential			

Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"In case of exclusion due to suicidal tendencies, help was provided in form of emergency phone numbers and webpages of health services. "



13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see Figure fort

13b) For each group, losses and exclusions after randomisation, together with reasons


Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see Figure fort

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.



Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Recruitment took place between April 18, 2018 and May 27, 2018"

"Patients were reassessed after 2 weeks (post-treatment, t1) and after 4 weeks

(t2) ne Antwort

14a-i) Indicate if critical "secular events" fell into the study period

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

	1	2	3	4	5	
subitem not at all important	\bigcirc	0	0	0	۲	essential

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Thertrial was ended once recruitment was completed.

15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

Does your paper address CONSORT subitem 15? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

see Tablet 1vand Table 2

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.



Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

SeeinTablet/vort

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

СО	NSORT-EH	EALTH (V 1	1.6.1) - Sub	mission/Pu	blication For	m	
16-i) Report multiple "c Report multiple "denominators" an range of study participation [and u than x times, N used more than y w specific pre-defined time points of clearly define "use" of the intervent	d provide se] thresh veeks, N p interest (definitior olds" [1], participan	ns: Report e.g., N ex ts "used"	N's (and posed, N the interv	effect size consentee ention/co	es) "across a d, N used more mparator at	
	1	2	3	4	5		
subitem not at all important	0	0	0	0	0	essential	
Does your paper address subitem 16-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study see Figure 1							
16-ii) Primary analysis should be intent-to-treat Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	0	essential	
Does your paper address subitem 16-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study							

We conducted complete-cases (CC) as well as intention-to-treat (ITT)

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

For primary nd secondary outcome, effect sizes and CI are displayed in

17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

	1	2	3	4	5	
subitem not at all important	\bigcirc	0	0	0	0	essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Weide Actveport binary outcomes.

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Moreover, we planned mediation analyses to investigate mechanism of change. We expected that an improvement in depressive symptoms at t2 would be mediated by change in activation (BADS) between t0 and t1. To further explore mechanism of change, we planned to also include change in mindfulness (KIMS-D) and dysfunctional cognitive biases (DAS) as mediators in exploratory analyses twort

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	\bigcirc	\bigcirc	0	\bigcirc	0	essential

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Negative effects were assessed by calculating the reliable change index (RCI) for clinically significant deterioration in the PHQ-9 from baseline to post assessment [42]."

"The deterioration rates were similar between groups ($\chi^2(2) = 1.47$, P = .48) with a mean deterioration rate of 6.8%."

19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].



Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable

19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

	1	2	3	4	5	
subitem not at all important	0	0	\bigcirc	0	0	essential

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Meine Antwort

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use). 1 2 3 4 5 subitem not at all

Does your paper address subitem 22-i?*


important

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The aim of the present study was to pilot the efficacy of iBA, a brief web-based module on behavior activation, in comparison with an active (iM) as well as a non-active control (CAU) intervention and to explore mechanisms of change." "Contrary to our expectation, the reduction of depressive symptoms (primary outcome) was similar in the experimental group (iBA) and the two control groups (iM and CAU)."

22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.



Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


"a longer intervention interval in combination with automated support, that is email reminders to use the intervention as well as the exercises, are an important next step to explore whether the present, single-module iBA intervention or the intervention period and usage needs to be extended and intensified. Moreover, it would be helpful to monitor the performed activities (and, e.g., to what degree physical activities were included)."

"Additional mechanisms of change should be assessed in future studies. The BA model extends to possible mechanisms such as reinforcement, mood, and avoidance of behavior (for example, described by [32]). It suggests the relationship between behavior activation and depression is mediated by an initial increase in positive reinforcement [for evidence in undergraduates see, 60]. These aspects of the BA theory should be

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.



Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Moreover, the current sample was quite experienced regarding psychological interventions for depression and activating or mindfulness treatment elements may have already been experienced by the participants in previous therapies and thus may not evolve the same effects as in treatment naïve MDD-patients (see Table 2). With the increasing number of available online interventions for psychological disorder, this may generally affect potential treatment samples for POIs. Expectations in the efficacy of a POI may generally be low if a participant did not benefit from an intervention before (or relapsed again), ultimately leading to a self-fulfilling prophecy that POIs do not help. This is also reflected by evidence showing that attitudes towards online interventions

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations


Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations



Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"depressive symptoms were rather mild in the current sample (means between 10.46 and 12.50 at baseline)"



Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Finally, due recruitment difficulties for the initial study protocol (use of the program in an outpatient clinic to bridge waiting times), changes in the trial protocol with regard to recruitment sources were unavoidable, which also need to be considered. "

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial was preregistered at The German Clinical Trials Register DRKS, #DRKS00011562.

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

not applicable

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The study was not externally funded.

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.




Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The authors do not have a conflict of interest.





🔵 yes, major changes

yes, minor changes

🔵 no

What were the most important changes you made as a result of using this checklist?

To calculate deterioration rates.

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *

10hours

As a result of using this checklist, do you think your manuscript has improved? *



🔵 no

Sonstiges:


Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document



🖲 no

) Sonstiges:



Dieser Inhalt wurde nicht von Google erstellt und wird von Google auch nicht unterstützt. <u>Missbrauch melden</u> - <u>Nutzungsbedingungen</u>

